Literature DB >> 27561426

Clinical proteomics in cancer: Where we are.

Carolina Panis1, Luciana Pizzatti2, Gustavo F Souza3, Eliana Abdelhay4.   

Abstract

Proteomics has emerged as a promising field in the post-genomic era. Notwithstanding the great advances provided by gene expression analysis in cancer, the lack of a correlation between gene expression and protein levels has highlighted the need for a proteomic focus on cancer. Although the increasing knowledge regarding cancer biology, a reliable marker to improve diagnosis, prognosis and treatment for cancer patients is not a reality at present. In this review, we address the main considerations regarding proteomics-based studies and their clinical applications on cancer research, highlighting some considerations related to strengths and limitations of proteomics-based studies and its application to clinical practice.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cancer; Clinical proteomics; Mass spectrometry; Oncoproteomics; Proteomics

Mesh:

Substances:

Year:  2016        PMID: 27561426     DOI: 10.1016/j.canlet.2016.08.014

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  5 in total

Review 1.  Sample Multiplexing Strategies in Quantitative Proteomics.

Authors:  Albert B Arul; Renã A S Robinson
Journal:  Anal Chem       Date:  2018-12-18       Impact factor: 6.986

2.  Ubiquitin and SUMO conjugation as biomarkers of acute myeloid leukemias response to chemotherapies.

Authors:  Pierre Gâtel; Frédérique Brockly; Christelle Reynes; Manuela Pastore; Yosr Hicheri; Guillaume Cartron; Marc Piechaczyk; Guillaume Bossis
Journal:  Life Sci Alliance       Date:  2020-04-17

3.  Cathepsin F and Fibulin-1 as novel diagnostic biomarkers for brain metastasis of non-small cell lung cancer.

Authors:  Song Wei; Wenwen Liu; Mingxin Xu; Huamin Qin; Chang Liu; Rui Zhang; Sihai Zhou; Encheng Li; Zhiyu Liu; Qi Wang
Journal:  Br J Cancer       Date:  2022-02-25       Impact factor: 9.075

4.  Convergence of pathway analysis and pattern recognition predicts sensitization to latest generation TRAIL therapeutics by IAP antagonism.

Authors:  Vesna Vetma; Cristiano Guttà; Nathalie Peters; Christian Praetorius; Meike Hutt; Oliver Seifert; Friedegund Meier; Roland Kontermann; Dagmar Kulms; Markus Rehm
Journal:  Cell Death Differ       Date:  2020-02-21       Impact factor: 15.828

5.  Histone-lysine N-methyltransferase SETD7 is a potential serum biomarker for colorectal cancer patients.

Authors:  Baojun Duan; Jun Bai; Jian Qiu; Jianhua Wang; Cong Tong; Xiaofei Wang; Jiyu Miao; Zongfang Li; Wensheng Li; Juan Yang; Chen Huang
Journal:  EBioMedicine       Date:  2018-10-22       Impact factor: 8.143

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.